MY206212A - Purified capsular polysaccharides of streptococcus pneumoniae - Google Patents

Purified capsular polysaccharides of streptococcus pneumoniae

Info

Publication number
MY206212A
MY206212A MYPI2021001583A MYPI2021001583A MY206212A MY 206212 A MY206212 A MY 206212A MY PI2021001583 A MYPI2021001583 A MY PI2021001583A MY PI2021001583 A MYPI2021001583 A MY PI2021001583A MY 206212 A MY206212 A MY 206212A
Authority
MY
Malaysia
Prior art keywords
streptococcus pneumoniae
capsular polysaccharides
purified capsular
purified
relates
Prior art date
Application number
MYPI2021001583A
Other languages
English (en)
Inventor
Rajendar Burki
Vivek Babu Kandimalla
Rajan Sriraman
Ramesh Venkat Matur
Narender Dev Mantena
Mahima Datla
Veerapandu Sangareddy
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69886702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY206212(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of MY206212A publication Critical patent/MY206212A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
MYPI2021001583A 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae MY206212A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841031653 2018-09-23
IN201841031654 2018-09-23
PCT/IB2019/058036 WO2020058963A1 (en) 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae

Publications (1)

Publication Number Publication Date
MY206212A true MY206212A (en) 2024-12-04

Family

ID=69886702

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021001583A MY206212A (en) 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae

Country Status (12)

Country Link
US (2) US12048739B2 (enExample)
EP (1) EP3852795A4 (enExample)
JP (2) JP2022513562A (enExample)
KR (1) KR102879391B1 (enExample)
CN (1) CN113164581A (enExample)
AU (1) AU2019341723C1 (enExample)
BR (1) BR112021005425A2 (enExample)
MX (1) MX2021003358A (enExample)
MY (1) MY206212A (enExample)
PH (1) PH12021550539A1 (enExample)
WO (1) WO2020058963A1 (enExample)
ZA (1) ZA202101663B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
ES3058336T3 (es) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
KR20220017996A (ko) * 2019-06-05 2022-02-14 머크 샤프 앤드 돔 코포레이션 면역원성 혈청형 35b 폐렴구균 폴리사카라이드-단백질 접합체 및 그를 제조하기 위한 접합 방법
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen
WO2022084852A1 (en) * 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CA3200602A1 (en) * 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP4288106A4 (en) * 2021-02-04 2025-06-04 Merck Sharp & Dohme LLC Lipid DNANOparticle adjuvant composition for pneumococcal conjugate vaccines
WO2024062494A1 (en) * 2022-09-19 2024-03-28 Biological E Limited Method for the purification of capsular polysaccharides
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
JP6502262B2 (ja) * 2012-12-20 2019-04-17 ファイザー・インク 糖複合化方法
PL3096786T3 (pl) * 2014-01-21 2021-11-08 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CA2968491C (en) 2014-11-20 2023-09-26 Biological E Limited Codon optimized polynucleotide for high level expression of crm197
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3374376B1 (en) 2015-11-09 2020-03-18 Biological E Limited Industrially scalable process for recovering biologically active recombinant carrier proteins
EP3436061A4 (en) * 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
NZ752348A (en) * 2016-09-30 2022-11-25 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
CN110366428B (zh) * 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
JP7680185B2 (ja) * 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
SMT202200356T1 (it) 2017-04-22 2022-11-18 Biological E Ltd Un metodo migliorato per produzione ad alto livello di crm
WO2019050814A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途

Also Published As

Publication number Publication date
WO2020058963A1 (en) 2020-03-26
KR20210062669A (ko) 2021-05-31
BR112021005425A2 (pt) 2021-06-15
AU2019341723B2 (en) 2024-03-21
US20240325516A1 (en) 2024-10-03
EP3852795A4 (en) 2022-11-23
ZA202101663B (en) 2024-08-28
CN113164581A (zh) 2021-07-23
US20210346488A1 (en) 2021-11-11
MX2021003358A (es) 2021-05-27
KR102879391B1 (ko) 2025-10-30
US12465632B2 (en) 2025-11-11
JP2022513562A (ja) 2022-02-09
PH12021550539A1 (en) 2022-02-21
AU2019341723A1 (en) 2021-05-20
JP2024160305A (ja) 2024-11-13
US12048739B2 (en) 2024-07-30
AU2019341723C1 (en) 2026-01-22
EP3852795A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
ZA202101663B (en) Purified capsular polysaccharides of streptococcus pneumoniae
WO2018226622A8 (en) Compounds for treating huntington's disease
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
MY191508A (en) Production of beta-lactoglobulin preparations
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
MX2017014891A (es) Producto de queso con almidones modificados.
WO2018081502A8 (en) Synthetic bacteriophages and bacteriophage compositions
PH12016501729B1 (en) Glycosyl hesperetin and process for producing the same and uses thereof
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2016000099A (es) Vacunas sinteticas contra streptococcus pneumoniae tipo 1.
EA201990451A1 (ru) Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
MX2021004467A (es) Productos lacteos filtrados acidos reducidos en carbohidratos.
WO2018004224A3 (ko) 신규 스포리치아과 미생물 및 그의 용도
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
MX2019010519A (es) Metodo de sintesis de cristales de zeolita con agente de siembra.
MY200521A (en) Raw material for producing a refractory product, use of said raw material, and a refractory product comprising such a raw material
ZA202100231B (en) Non-viable bifidobacterium bifidum bacteria and uses thereof
MX2020013380A (es) Producto refractario, una mezcla para la fabricacion del producto, un procedimiento para la fabricacion del producto asi como un uso del producto.
MX2020007246A (es) Diseño de vacuna integral para el avance de enfermedad comensal.
EA202190824A1 (ru) Очищенные капсульные полисахариды streptococcus pneumoniae
PL409330A1 (pl) Szczepy Staphylococcus aureus do produkcji monoklonalnych preparatów fagowych pozbawionych zanieczyszczeń plazmidowym DNA
MX2020007906A (es) Composicion que comprende nuevas cepas de lactobacillus salivarius y metodo para la prevencion y el tratamiento de otitis e infecciones respiratorias de vias altas.
WO2020013772A3 (en) Method for producing a condensed dairy product